3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Leukemia
5
Neoplasms by Histologic Type
4
Neoplasms
4
Myeloproliferative Disorders
4
Leukemia, Myeloid
4
Hematologic Diseases
4
Bone Marrow Diseases
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myeloid, Chronic-Phase
3
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Hematologic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Blast Crisis
1
Interventions
Imatinib Mesylate
26
Sunitinib
22
nilotinib
12
ripretinib
11
regorafenib
7
avapritinib
7
tanespimycin
2
pexidartinib
2
masitinib
2
famitinib
2
Midazolam
2
IDRX-42
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
umbralisib
1
trastuzumab deruxtecan
1
trametinib
1
tinostamustine
1
spartalizumab
1
ribociclib
1
repaglinide
1
ponatinib
1
perifosine
1
pembrolizumab
1
olverembatinib
1
olaratumab
1
motesanib diphosphate
1
dabrafenib
1
cediranib
1
binimetinib
1
anlotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gastrointestinal Stromal Tumors
×
ponatinib
×
Clear all
NCT01874665
2018-05-18
GIST
Takeda
Phase 2
Completed
45 enrolled
21 charts